C
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Price:
107
TWD
Market Cap:
NT$166.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
TW |
Balance Sheet
Balance Sheet Decomposition
Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd
Balance Sheet Decomposition is not available for
Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd
Balance Sheet
Caliway Biopharmaceuticals Co Ltd
Caliway Biopharmaceuticals Co Ltd
Currency: TWD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
22
|
94
|
595
|
655
|
3 422
|
6 901
|
784
|
|
| Cash |
22
|
94
|
595
|
580
|
3 054
|
789
|
439
|
|
| Cash Equivalents |
0
|
0
|
0
|
75
|
368
|
6 113
|
346
|
|
| Short-Term Investments |
0
|
0
|
0
|
456
|
289
|
2 767
|
4 076
|
|
| Total Receivables |
8
|
0
|
0
|
3
|
8
|
5
|
6
|
|
| Accounts Receivables |
3
|
0
|
0
|
3
|
8
|
5
|
6
|
|
| Other Receivables |
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
3
|
0
|
3
|
1
|
3
|
3
|
|
| Other Current Assets |
9
|
15
|
10
|
15
|
23
|
29
|
122
|
|
| Total Current Assets |
38
|
111
|
605
|
1 132
|
3 744
|
9 706
|
4 991
|
|
| PP&E Net |
129
|
115
|
106
|
100
|
80
|
61
|
51
|
|
| PP&E Gross |
129
|
115
|
106
|
100
|
80
|
61
|
51
|
|
| Accumulated Depreciation |
29
|
45
|
58
|
80
|
107
|
134
|
157
|
|
| Intangible Assets |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
4 425
|
|
| Other Long-Term Assets |
1
|
1
|
1
|
1
|
2
|
3
|
8
|
|
| Total Assets |
170
N/A
|
227
+33%
|
713
+214%
|
1 233
+73%
|
3 827
+210%
|
9 771
+155%
|
9 474
-3%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
1
|
0
|
3
|
2
|
1
|
1
|
|
| Accrued Liabilities |
20
|
45
|
31
|
33
|
62
|
37
|
35
|
|
| Short-Term Debt |
5
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
81
|
15
|
8
|
8
|
9
|
9
|
3
|
|
| Other Current Liabilities |
3
|
4
|
0
|
5
|
1
|
6
|
6
|
|
| Total Current Liabilities |
110
|
64
|
40
|
48
|
74
|
53
|
45
|
|
| Long-Term Debt |
69
|
116
|
29
|
20
|
12
|
3
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
18
|
18
|
|
| Total Liabilities |
180
N/A
|
180
+0%
|
68
-62%
|
69
+1%
|
86
+24%
|
74
-14%
|
64
-14%
|
|
| Equity | ||||||||
| Common Stock |
245
|
292
|
536
|
616
|
697
|
769
|
777
|
|
| Retained Earnings |
273
|
350
|
107
|
286
|
227
|
56
|
80
|
|
| Additional Paid In Capital |
19
|
107
|
217
|
834
|
3 271
|
9 131
|
8 753
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
131
|
|
| Other Equity |
0
|
1
|
1
|
0
|
1
|
147
|
73
|
|
| Total Equity |
9
N/A
|
47
N/A
|
645
+1 284%
|
1 164
+81%
|
3 741
+221%
|
9 697
+159%
|
9 410
-3%
|
|
| Total Liabilities & Equity |
170
N/A
|
227
+33%
|
713
+214%
|
1 233
+73%
|
3 827
+210%
|
9 771
+155%
|
9 474
-3%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
62
|
62
|
62
|
0
|
1 393
|
1 538
|
1 553
|
|
Switch to:
Switch to:
See Also
Discover More
